MY PICK IS ELN

[New-born baby]

Euro dropping in value

France voted down the EU constitution. Puts the whole thing in jeopardy. That will be interesting to see what happens next.

[Websman]

Let's take a small poll...How many of you are holding ELN?

[Runner]

Webs, I sold it a few days ago.

[Websman]

I still have some room to play with. Biogen has their annual shareholders meeting on Friday. If they have any good news it should send ELN up a little more.

[Runner]

Webs, One of my rules for swings/short term trading is to clean the house when I see an evening doji. That one signal was all I needed to see. I hope ELN rocks for ya.

[kingofthehill]

from Davy Brokers in Ireland, stock should move up today based on this alone

• Elan announced this morning that it has retired $211.8 m of its 2008 outstanding debt and has agreed to retire a further
$31.0m, which is expected to close within the next few days. Retiring the debt early is a clear positive for Elan as this removes
medium-term financial risk while it continues to focus on Tysabri.
• Cash balances at the end of March 2005 will be reduced by about $80m but remain in excess of $1.3bn. These
transactions will result in no additional share dilution and will reduce annual interest cost by about $16m.
• Elan purchased $175.0m and agreed to purchase a further $31.0m in aggregate principal amount of 6.5% convertible
guaranteed notes due 2008 for approximately $255.0m at an average premium of approximately 4% to the market price of
the convertible notes at the date of purchase.
• Elan has also purchased $36.8m in aggregate principal amount of the 7.25% senior notes due 2008 (Athena Notes) for
$33.3m plus accrued interest of $0.6m.
• As a result of these transactions, Elan will record a net charge of approximately $53m in the second quarter of 2005, of
which approximately $48m will be cash and approximately $5m will be non-cash unamortised financing costs. After
deducting this charge and giving effect to these repurchases, shareholders’ equity at March 31st 2005 would have increased
by approximately $153m, and Elan's annual interest charge will be reduced by approximately $16m.

[noshadyldy]

Great Vulcan one,
I'm still in and at this point have decided to STAY in. I've been in and out several times and have compared what I've made to what I could have made if I wasn't trying to be so savvy and time the darn thing. I so firmly believe that this drug MUST return as there is tremendous pressure from the MS community to bring it back. I'm sure there are others on this board who were more successful than I in timing the stock's ups and downs, but for someone of mediocre skill, I'm better off staying put. I'll just need some maalox from time to time is all.

[Websman]

I have the same problem Noshady. I'm too busy working to try to catch the ups and downs just right, so I'm also going to keep my ELN shares for a while.

It may not go far for a month or two, but when or if Tysabri is reintroduced, you better hang on tight, because it's going to be one heck of a ride. There's nothing like a quick $10-20 move.

[Runner]

Not sure if any news is out, but my type is showing ELN @ 6.25. I hope this thing holds for those of you holding. I have not yet seen any volume on it this early. I will say the market has been really crazy lately.

[noshadyldy]

RATS! Just as I make my resolve to hang in there steady. (Webs can I cry in your beer?)
Anyway, lets take a look here, this fourth patient was also on a second med, the same med that the first two were on. A black label is a sure thing. Drug extinction isn't. However, it's sure gonna hurt for now.

[noshadyldy]

By the way, maalox now comes in a 'wild berry' flavor. it's my favorite!
Cheers!

[kingofthehill]

todays action reprint from Yahoo ELN board


Dear sir or madam:

You are aware of the article in the Boston Globe today which declared that a fourth fatality had occurred connected to the use of Tysabri. The claims of this article are materially false.

This latest possible case has not even been declared PML. Nor has the person died, contrary to the article's headline on Page One. For that matter, the second discovered case of PML has not ended in death, so the headline's count is twice wrong.

This last possible case had only 1 to 3 doses of Tysabri. Tysabri has several linear years and thousands of patient-years of safe use under exhaustive review. Is it suddenly feasible that it has become this lethal a killer?

More likely is that the severe reactions this patient had were due - as in all other Tysabri-related PML cases - to the use of other immunosuppresants.

We do not know the medical history of this patient, including possible use of other immunoregulators.

We do know that news of a non-material event was dug up by the Boston Globe and trumpeted to the public, causing the loss of a billion dollars to investors and perhaps affecting the eventual return of Tysabri by increasing political pressure on the FDA.

This is an unconscionable use of the power of journalism. Exactly what checks and balances are on these recipients of public trust? The potential for abuse of position, including even for personal aggrandizement, is enormous.

Would that the Globe had used its investigative energies to distinguish between the safety of Tysabri for monotherapy, where there have been no severe side effects whatsoever, and the combination therapy which indeed has caused problems.

I truly hope that the entire Tysabri saga, and this latest chapter in particular, is the cause for the SEC to investigate the manipulation of the market through the advancement of false information and the suppression of actual facts. Between the state of financial journalism, the free reign given hedge funds (ELN has been on the Regulation SHO list for over two weeks now), and the legal and political minefield the drug companies must traverse, the small investor, who is the strength of the American economy, is literally being driven out of the stock market.

How many life-changing medications have been delayed or scuttled entirely for these reasons? For the good of the nation, this activity must be reined in.

Sincerely,
Paul ...

cc: [email protected]

[jiesen]

How many life-changing medications have been delayed or scuttled entirely for these reasons?

LJPC's Riquent, for one. FDA was about to grant a subpart-H approval when they suddenly clammed up due in part to political fallout from Vioxx and other recent "failures" of FDA oversight like the antidepressants and Tysabri.

For the good of the nation, this activity must be reined in.

Couldn't agree more!

[Websman]

By the way, maalox now comes in a 'wild berry' flavor. it's my favorite!
Cheers!

ouch... That hurt. I got clipped pretty good on that trade. I got out before any more damage could be done.


ELN is a real S.O.B. It's not all bad though. I still have some of last years profits in my account. They didn't get it all. It's just going to be a little harder to get that 100 gain this year.

I'll take some of that 'wild berry' maalox. It'll go great with our beer.

Now...bring on the next winning stock!

[Websman]

LJPC's Riquent, for one. FDA was about to grant a subpart-H approval when they suddenly clammed up due in part to political fallout from Vioxx and other recent "failures" of FDA oversight like the antidepressants and Tysabri.



Couldn't agree more!

There's a strong possibility that ELN may very weel be the victim of "naked shorting". If the SEC doesn't find a solution for this problem the markets will suffer severely.